NASDAQ:YDES YD Bio (YDES) Stock Price, News & Analysis $4.88 -0.32 (-6.15%) Closing price 04:00 PM EasternExtended Trading$4.88 0.00 (-0.10%) As of 04:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOwnershipSEC FilingsShort Interest About YD Bio Stock (NASDAQ:YDES) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get YD Bio alerts:Sign Up Key Stats Today's Range$4.88▼$5.4550-Day Range$2.63▼$8.1152-Week Range$1.70▼$15.72Volume24,881 shsAverage Volume142,118 shsMarket Capitalization$345.46 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview YD Bio Limited is a biotechnology company focused on the development of DNA methylation-based cancer detection technologies and ophthalmologic innovations. The company also provides clinical trial support and related research services. YD Bio Limited is headquartered in Taipei, Taiwan, and its ordinary shares trade on the Nasdaq Global Market under the ticker symbol YDES. Read More YD Bio Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks32nd Percentile Overall ScoreYDES MarketRank™: 1.584281417545 of 5 starsYD Bio scored higher than 32% of companies evaluated by MarketBeat, and ranked 788th out of 892 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.5 / 5Analyst RatingSell Consensus RatingYD Bio has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageYD Bio has received no research coverage in the past 90 days.Read more about YD Bio's stock forecast and price target. Earnings and ValuationN/AProj. Earnings GrowthN/A Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.26% of the float of YD Bio has been sold short.Short Interest Ratio / Days to CoverYD Bio has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in YD Bio has recently decreased by 2.51%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldYD Bio does not currently pay a dividend.Dividend GrowthYD Bio does not have a long track record of dividend growth. News and Social Media3.6 / 5News Sentiment0.83 News SentimentYD Bio has a news sentiment score of 0.83. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 4 news articles for YD Bio this week, compared to 1 article on an average week.Search Interest1 people have searched for YDES on MarketBeat in the last 30 days. Company Ownership2.1 / 5Insider TradingAcquiring Shares Net Insider BuyingOver the last three months, insiders have purchased a net $12,183.00 in company stock, which represents 0.0035% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, YD Bio insiders have bought more of their company's stock than they have sold. Specifically, they have bought $12,183.00 in company stock and sold $0.00 in company stock.Percentage Held by InstitutionsYD Bio has minimal institutional ownership at this time.Read more about YD Bio's insider trading history. Receive YDES Stock News and Ratings via Email Sign-up to receive the latest news and ratings for YD Bio and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. YDES Stock News HeadlinesYD Bio Expects FDA Feedback On Dry Eye Candidate By January 4, 20272 hours ago | rttnews.comYD Bio (NASDAQ:YDES) Share Price Crosses Below Two Hundred Day Moving Average - Here's What HappenedNovember 13 at 4:01 AM | americanbankingnews.comTrump’s EO to send this $5 stock ripping higher…?President Trump's December executive order declared space a national security and economic priority, fueling a race among SpaceX, Blue Origin, and others to build massive satellite constellations. One tiny firm holds the patented tech required to transmit satellite data to Earth at scale - and it reportedly powers SpaceX's most profitable division. Shares trade for under 5 dollars. Former JPMorgan wealth manager Ross Givens says it's the most uniquely positioned stock he's seen in 20 years of trading.November 13 at 1:00 AM | Traders Agency (Ad)YD Bio Announces FDA Grant of INTERACT Meeting Request for YDB-LMSCEV-001, an Investigational Extracellular Vesicle Candidate for Dry Eye DiseaseNovember 12 at 4:30 PM | globenewswire.comYD Bio and EG BioMed Partner with JoiiUp to Launch AI-Driven Cancer Risk Assessment for Corporate Wellness ProgramsOctober 20, 2026 | globenewswire.comYD Bio and EG BioMed Launch AI-Based 10-Cancer Risk Factor AssessmentOctober 6, 2026 | globenewswire.comYD Bio Ltd (YDES)September 1, 2026 | finance.yahoo.comYD Bio Files First-Half 2026 Results, Reports Improved Equity PositionSeptember 1, 2026 | tipranks.comSee More Headlines YDES Stock Analysis - Frequently Asked Questions How have YDES shares performed this year? YD Bio's stock was trading at $12.19 at the beginning of 2026. Since then, YDES stock has decreased by 60.0% and is now trading at $4.88. How were YD Bio's earnings last quarter? YD Bio Limited (NASDAQ:YDES) announced its earnings results on Tuesday, September, 1st. The biotechnology company reported $0.05 earnings per share for the quarter. The biotechnology company earned $423.25 thousand during the quarter. How do I buy shares of YD Bio? Shares of YDES stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings9/01/2026Today11/13/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (2m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 YDES's financial health is in the Green zone, according to TradeSmith. YDES has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:YDES CIK2011674 Webwww.ydesgroup.com Phone(822) 546-1611FaxN/AEmployees14Year Founded2025Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares70,790,000Free FloatN/AMarket Cap$345.46 million OptionableN/A Beta-1.20 Social Links 10 Best Stocks to Own in Fall 2026AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.Get This Free Report This page (NASDAQ:YDES) was last updated on 11/13/2026 by MarketBeat.com Staff. From Our PartnersTrump’s EO to send this $5 stock ripping higher…?President Trump's December executive order declared space a national security and economic priority, fueling a...Traders Agency | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...Paradigm Press | SponsoredWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredUranium Mine Flood That Sparked a 2006 Price Surge ReturnsIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...Digest Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding YD Bio Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share YD Bio With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
